Multiple sclerosis with mite antigen-specific IgE

被引:16
|
作者
Kira, J [1 ]
Kawano, Y [1 ]
Yamasaki, K [1 ]
机构
[1] Kyushu Univ 60, Fac Med, Inst Neurol, Dept Neurol, Fukuoka 81282, Japan
关键词
multiple sclerosis; IgE; atopy; mite; HLA;
D O I
10.1016/S0022-510X(98)00025-2
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The total and mite antigen-specific IgE in the sera were measured in 60 patients with multiplesclerosis (MS) and 40 healthy controls by an enzyme-linked immunosorbent assay using two common mite antigens, Dermatophagoides farinae and Dermatophagoides pteronyssinus, in order to study the role of atopy in MS. Neither the total IgE level nor the frequency of mite antigen-specific IgE differed significantly between the MS patients (mean total IgE 162 U/ml, 42% mite IgE-positive) and healthy controls (mean total IgE 168 U/ml, 35% mite IgE-positive). The MS patients with mite antigen-specific IgE showed a significantly higher level of serum total IgE (mean 293 U/ml, P=0.0005) and a higher frequency of atopic disorders (36%, P=0.0508) than did the MS patients without mite antigen-specific IgE (mean total IgE 68 U/ml, atopic disorders 14%). The former group also showed a significantly higher frequency of male (P=0.0216), a younger age of onset (P=0.0081), a lower expanded disability status scale (EDSS) score (P=0.03) and a lower protein content in the cerebrospinal fluid (CSF) (P=0.0426) than the latter, while the duration of disease and a number of relapses did not differ significantly between the two groups. In addition, the mite IgE-positive MS showed a very low frequency of oligoclonal IgG bands in CSF (4%) and a significantly higher association of HLA-A24 (87.5%) than the healthy controls (45%). Therefore, the presence of IgE response to the mite antigens and atopy appeared to significantly lessen the severity of the disease and the immunologic abnormalities in MS. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:138 / 142
页数:5
相关论文
共 50 条
  • [1] Antigen-specific therapies in multiple sclerosis
    Sospedra, M
    Martin, R
    INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2005, 24 (5-6) : 393 - 413
  • [2] Antigen-specific therapies in multiple sclerosis
    Giacomini, Paul S.
    Bar-Or, Amit
    EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (03) : 551 - 560
  • [3] Antigen-specific therapies in multiple sclerosis
    van Noort, JM
    BIOTHERAPY, 1998, 10 (03) : 237 - 250
  • [4] Antigen-specific therapy for multiple sclerosis
    Sarah Crunkhorn
    Nature Reviews Drug Discovery, 2021, 20 (1) : 20 - 20
  • [5] Antigen-specific tolerization approaches in multiple sclerosis
    Lutterotti, Andreas
    Martin, Roland
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (01) : 9 - 20
  • [6] CALCULATIONS OF ANTIGEN-SPECIFIC IGE
    SCHELLENBERG, RR
    ADKINSON, NF
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1976, 57 (05) : 512 - 512
  • [7] MYELIN ANTIGEN-SPECIFIC FORMS OF MULTIPLE-SCLEROSIS
    WARREN, KG
    CATZ, I
    NEUROLOGY, 1994, 44 (04) : A300 - A301
  • [8] The coming of age for antigen-specific therapy of multiple sclerosis
    Steinman, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (08) : 793 - 794
  • [9] Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis
    Kammona, Olga
    Kiparissides, Costas
    BRAIN SCIENCES, 2020, 10 (06)
  • [10] Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis
    McFarland, HI
    Lobito, AA
    Johnson, MM
    Palardy, GR
    Yee, CSK
    Jordan, EK
    Frank, JA
    Tresser, N
    Genain, CP
    Mueller, JP
    Matis, LA
    Lenardo, MJ
    JOURNAL OF IMMUNOLOGY, 2001, 166 (03): : 2116 - 2121